Cyclin Dependent Like Kinase 5 (SerineThreonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 20170

ReportsWorldwide has announced the addition of a new report title Cyclin Dependent Like Kinase 5 (SerineThreonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.

Summary
According to the recently published report 'Cyclin Dependent Like Kinase 5 - Pipeline Review, H2 2017'; Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) pipeline Target constitutes close to 6 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Cell division protein kinase 5 is an enzyme encoded by the CDK5 gene. It does not directly control cell cycle regulation. Instead it functions in diverse processes such as synaptic plasticity and neuronal migration through phosphorylation of proteins required for cytoskeletal organization, endocytosis and exocytosis, and apoptosis. Dysregulation of this enzyme is involved in several neurodegenerative diseases including Alzheimer's disease and invasive cancers.

The report 'Cyclin Dependent Like Kinase 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology and Metabolic Disorders which include indications Alzheimer's Disease, Breast Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Lung Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuroblastoma, Obesity, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Type 2 Diabetes and Uterine Cancer.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

To Enquire about this Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41780

Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1)
- The report reviews Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) targeted therapeutics

Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/cyclin-dependent-like-kinase-5-serinethreonine-protein-kinase-pssalre-or-tau-protein-kinase-ii-catalytic-subunit-or-cell-division-protein-kinase-5-or-cdk5-or-ec-27111-pipeline-review-h2-2017

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.